The combination of PIN1 inhibitor and CDK4 inhibitor thus enhances anti-tumor immunity, with decreased Tregs, increased cytotoxic T cells and evidence for tumor cell phagocytosis, raising the possibility that this rewiring of the immune system could further improve the therapeutic effect. Here, PIN1 is linked to neoplasm.